Literature DB >> 15893625

Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen.

Angie Westwood1, Gareth D Healey, E Diane Williamson, Jim E Eyles.   

Abstract

We have carried out an in vitro investigation into the mechanism by which microencapsulation enhances the immunogenicity of recombinant protective antigen (rPA) from Bacillus anthracis. Murine bone marrow derived dendritic cells (DC) were cocultured with soluble and microencapsulated rPA and the activation status of the cells monitored using FACS. As compared with soluble rPA, it was found that coculture of DC with rPA-loaded microparticles stimulated higher levels of MHC II, CD54, CD80 and CD86 expression (p<0.05). To investigate the longevity of antigen presentation, splenocytes from naïve mice were pulsed overnight with (3)H-thymidine following 1, 3 or 6 days coculture with DC transiently exposed to soluble or microencapsulated rPA. Splenocyte proliferation was more pronounced, and continued for a more protracted period, if the 'feeder' cells were exposed to microencapsulated antigen as compared with soluble antigen or 'empty' microspheres. To this end, our findings indicate that microsphere uptake increases the surface expression of MHC and co-stimulatory molecules on DC and can facilitate prolonged presentation of antigen to T-cells, possibly by acting as an intracellular depot.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893625     DOI: 10.1016/j.vaccine.2004.11.079

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.

Authors:  Mauricio A Arias; Andrew Loxley; Christy Eatmon; Griet Van Roey; David Fairhurst; Mark Mitchnick; Philip Dash; Tom Cole; Frank Wegmann; Quentin Sattentau; Robin Shattock
Journal:  Vaccine       Date:  2010-12-09       Impact factor: 3.641

Review 2.  Demystifying particle-based oral vaccines.

Authors:  Pedro Gonzalez-Cruz; Harvinder Singh Gill
Journal:  Expert Opin Drug Deliv       Date:  2021-07-06       Impact factor: 8.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.